A randomized trial Comparing the Effects of Febuxostat and Allopurinol on renal function and left ventricular hypertrophy for chronic heart failure patient with hyperuricemia complicated by chronic kidney disease stage G3-G4.

A randomized trial Comparing the Effects of Febuxostat and Allopurinol on renal function and left ventricular hypertrophy for chronic heart failure patient with hyperuricemia complicated by chronic kidney disease stage G3-G4. - CEFIRO study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014309

Enrollment

Registered

2014-06-19

Start date

2014-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure patients with hyperuricemia

Interventions

Febuxostat group: Patients take febuxostat by oral administration for 52 weeks (approximately one year). Chronic heart failure patient with hyperuricemia (Uric acid more than 7mg/dl) are scheduled t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Male or female outpatients over 20 years old at time the subjects sign the Informed Consent Form (ICF). 2) Serum uric acid level >7.0 mg/dL 3) Without taking drugs lowered uric acid within 3 month before the treatment start 4) CHF, NYHA functional class II - III and systolic dysfunction, LVEF<40% 5) Stable for heart failure, without changes in NYHA functional class 6) The eGFR of the patients are between 15 and 60 ml/min/1.73m2. 7) Written informed consent by his/her own will.

Exclusion criteria

Exclusion criteria: 1) Patients who have allergy to febuxostat or allopurinol. 2) Patients who take mercaptopurine or azathioprine. 3) Nephrotic syndrome,dialysis patients,renal transplant or on other serious disease 4) Patients with AST or ALT level over than the twice the facilitie standard value. 5) Patients who have complication of malignant tumor. 6) Pregnant, possibly pregnant, brest-feeding, or expecting to conceive. 7) Written informed consent by his/her own will not. 8) Patients who are judged as inadequate to participate the study by the their doctors.

Design outcomes

Primary

Measure	Time frame
eGFR slope (change of eGFR from the baseline to 52 weeks)	—

Secondary

Measure	Time frame
1) Cardiac function indexes on echocardiography (LVEF, LVMI, LVEDV, LVESV, %FS, RWT) and (E, A, DT, E/e') 2) The amount of change of serum uric acid value and BNP 3) The amount of change of urine protein,urinecreatinine, the albumin urine/creatinine ratio and the albumin urine 4) The amount of change of eGFR and cystatin C 5) The amount of change of L-FABP and o-LDL 6) The amount of change of hsCRP 7) The amount of change of EPA/AA 8) Achievement quotient of serum uric level urine 6.0mg/dl 9) Incidence of adverse event	—

Measure

Time frame

1) Cardiac function indexes on echocardiography (LVEF, LVMI, LVEDV, LVESV, %FS, RWT) and (E, A, DT, E/e') 2) The amount of change of serum uric acid value and BNP 3) The amount of change of urine protein,urinecreatinine, the albumin urine/creatinine ratio and the albumin urine 4) The amount of change of eGFR and cystatin C 5) The amount of change of L-FABP and o-LDL 6) The amount of change of hsCRP 7) The amount of change of EPA/AA 8) Achievement quotient of serum uric level urine 6.0mg/dl 9) Incidence of adverse event

—

Countries

Japan

Contacts

Public ContactToshiharu Takeuchi

Asahikawa Medical University Cardiovascular Respiratory and Neurology Division, Department of Internal Medicine

take21@asahikawa-med.ac.jp0166-68-2442

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026